MedPath

Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis

Not Applicable
Completed
Conditions
Brain Metastases
Radiation Necrosis
Registration Number
NCT05762172
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Brief Summary

Contrast-enhanced magnetic resonance imaging is the most widely used examination for detecting the presence of brain metastasis. Functional sequences such as perfusion weighted imaging makes it possible to differentiate tumor recurrence from cerebral radionecrosis. However, this imaging technique may exhibit limitations, especially for brain lesions consisting of a mixture of necrotic tissue and tumor progression or depending on the location of the lesion in the brain. The use of 18F-DOPA PET is another option available to oncologists. Many studies on gliomas showed the superiority of this imaging technique over contrast-enhanced MRI. However, this imaging solution has been very poorly studied for brain metastases. The new PET technology equiped with silicon detectors makes it possible to obtain greater sensitivities than those of previous generations. It also make possible to obtain images in very short acquisition times. After injection, the hardware allows to obtain the perfusion kinetics of the lesion thanks to a very short temporal sampling (i.e. three seconds).

The main objective of this pilot study is to evaluate the association between early activity measurements (\< 4 minutes post-injection) of 18F-FDOPA in PET and the differential diagnosis between radionecrosis and recurrence of cerebral metastases treated by radiotherapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • Patient referred for cerebral 18F-FDOPA PET examination prescribed as part of his usual medical care for brain metastasis
  • Age ≥ 18 years old
  • Affiliation to a social security program
  • Ability of the subject to understand and express opposition
Exclusion Criteria
  • Age under 18
  • Person under guardianship or curators
  • Pregnant woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
difference between the maximum activity (in Bq/mL) in the venous sinus and the maximum activity present in the region of interest encompassing the lesion being studied.30 minutes
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Amiens

🇫🇷

Amiens, Picardie, France

© Copyright 2025. All Rights Reserved by MedPath